NEW YORK (GenomeWeb News) – SuperGen said today that it will screen epigenetic targets for cancer drugs for GlaxoSmithKline, under an agreement announced today.

The Dublin, Calif.-based drug screening and development firm said that it will receive $5 million up front, which includes a $3 million investment from the UK drug maker. It also said that milestone and royalty payments from GSK for development and commercialization could potentially surpass $375 million, and it could also receive tiered royalties reaching double-digits on products derived from the collaboration.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genomic study of group B Streptococcus evolution, selection on the X chromosome in great apes, and more.

Changing the fat and fiber content of people's diets affects their gut microbiome, metabolome, and colon cancer risk, researchers say.

Broken links are found throughout academic publications, and some services are trying to combat such link decay.

Nick Stockton at Wired says that a pause in studying genome-editing tools should be used to find a path forward.